Pleural Metastasis: Causes, Symptoms, and Treatment

Pleural metastasis occurs when cancer cells from a primary tumor spread to the thin membranes lining the lungs and chest wall, often triggering a buildup of fluid called a malignant pleural effusion (MPE). Lung and breast cancers are the most common culprits, though cancers originating in the ovaries, gastrointestinal tract, and other distant sites can also seed the pleural space. The condition marks an advanced stage of disease and shapes treatment decisions in ways that go well beyond simply draining fluid.

How Cancer Reaches the Pleura

Cancers that sit close to the pleura, like lung and breast adenocarcinomas, can invade it directly by growing through adjacent tissue. But tumors located far from the chest, such as ovarian or gastrointestinal cancers, appear to use more active biological mechanisms to establish themselves in the pleural space.¹ These routes include spread through the bloodstream, migration through the lymphatic system, or direct extension through the diaphragm from abdominal tumors.

Once tumor cells arrive, they do not simply sit passively. They orchestrate an inflammatory environment that promotes fluid accumulation. Tumor cells trigger signaling cascades that increase inflammation, stimulate the growth of new blood vessels, and make existing blood vessels leak. Tumor-derived molecules recruit immune cells and amplify vascular changes, while host cells in the pleura perpetuate these signals in a self-reinforcing loop.² The result is a progressive accumulation of protein-rich fluid that compresses the lung and causes the symptoms patients experience.

Symptoms and When They Appear

Breathlessness and cough are the hallmark symptoms at presentation.³ The breathlessness tends to come on gradually as fluid collects, and patients often describe it as a tightness or inability to take a full breath, especially with exertion. Chest pain, when it occurs, is typically dull and one-sided, sometimes worsening with deep breaths. Some patients experience unintentional weight loss and fatigue, which can reflect both the underlying cancer and the metabolic burden of a large effusion.

A tricky aspect of pleural metastasis is that small effusions can be completely silent. They are sometimes discovered incidentally on imaging ordered for unrelated reasons or during routine cancer staging scans. By the time symptoms drive someone to a doctor, the effusion is often large enough to occupy a substantial portion of one side of the chest.

Getting to a Diagnosis

When a pleural effusion is discovered in a patient with known cancer, the clinical suspicion for pleural metastasis is immediately high. But confirming it matters because not every effusion in a cancer patient is malignant. Infections, heart failure, pulmonary embolism, and radiation therapy can all produce fluid buildup that mimics MPE. The diagnostic path usually moves through imaging, fluid sampling, and sometimes biopsy.

Imaging

A standard chest CT with contrast is the first-line imaging tool and can reveal the effusion itself along with pleural thickening, nodules, or masses that suggest tumor implants. When the CT findings are ambiguous, PET/CT scanning adds useful information. In patients with non-small cell lung cancer whose CT results were indeterminate, PET/CT achieved about 71% diagnostic accuracy for pleural metastasis, outperforming contrast-enhanced CT alone.⁴ PET/CT works by detecting metabolically active tissue that takes up a glucose-based tracer, and pleural tumor deposits light up on the scan.⁵

One area where imaging becomes especially important is telling pleural metastasis apart from malignant pleural mesothelioma, a primary cancer of the pleura. Features like circumferential thickening, diaphragmatic involvement, and the pattern of pleural nodules differ between the two conditions, and machine-learning models trained on CT features have shown strong discrimination between them.⁶ This distinction matters because the treatment and prognosis differ substantially.

Fluid Analysis

Draining some of the effusion and sending it for cytology, where a pathologist examines the fluid under a microscope for cancer cells, is a standard diagnostic step. A meta-analysis pooling over 6,000 patients found that pleural fluid cytology correctly identified malignancy about 58% of the time overall, though the sensitivity varies enormously by cancer type.⁷ Lung adenocarcinoma cells are relatively easy to spot (sensitivity around 84%), while squamous cell lung cancer and mesothelioma are much harder to pick up on cytology alone (roughly 24% and 29%, respectively). Among cancers from outside the chest, ovarian cancer has a high detection rate (about 85%), while breast cancer falls in the middle range (about 65%).

A negative cytology result does not rule out malignancy. In one retrospective study, initial cytology was diagnostic in about three-quarters of cases, with lung cancer at 79% and breast cancer at 91%.⁸ But a substantial share of patients need a second tap or a more invasive procedure to confirm the diagnosis.

Pleural Biopsy

When fluid cytology comes back negative or inconclusive, pleural biopsy is the next step. Both image-guided needle biopsy (using ultrasound or CT) and medical thoracoscopy, where a small camera is inserted through the chest wall to directly visualize and sample the pleura, are superior to older blind biopsy techniques.⁹

A large network meta-analysis of 64 studies and nearly 9,000 patients found that rigid medical thoracoscopy had the highest diagnostic yield at 95%, with cryobiopsy and semirigid thoracoscopy close behind at roughly 93% each. Closed (blind) pleural biopsy had the lowest yield at about 75%.¹⁰ In practice, the choice between image-guided biopsy and thoracoscopy often depends on local availability and the patient’s fitness for the procedure, since the overall diagnostic yield is similar for both when performed well.⁹

Managing Malignant Pleural Effusions

The immediate goal of treatment for most patients with pleural metastasis is symptom relief, especially alleviating the breathlessness caused by fluid. The two most established approaches are pleurodesis and indwelling pleural catheters (IPCs), and a fair amount of research has gone into comparing them.

Pleurodesis

Pleurodesis aims to seal the pleural space permanently so fluid cannot reaccumulate. A substance, most commonly talc, is introduced into the space to provoke an intense inflammatory reaction that causes the two pleural layers to stick together. Talc is the most effective agent available. A meta-analysis of 24 studies found it produced higher pleurodesis success rates than all other chemical agents, and it outperformed bleomycin specifically.¹¹ A Cochrane review confirmed talc’s superiority, finding that the chance of the effusion not recurring was about 34% higher with talc compared with bleomycin, tetracycline, or tube drainage alone.¹²

Talc can be delivered in two ways: as a slurry through a chest tube at the bedside, or as a dry powder (poudrage) blown directly onto the pleural surface during thoracoscopy. A randomized trial showed that thoracoscopic poudrage had a recurrence rate of just 13% out to six months, compared with 65% for bleomycin instilled through a chest tube.¹³ The downside is that pleurodesis typically requires a hospital stay of several days and works best when the lung can fully re-expand to make contact with the chest wall.

Indwelling Pleural Catheters

An IPC is a thin, flexible tube tunneled under the skin and into the pleural space. Patients or caregivers can drain fluid at home whenever symptoms return, usually every few days. IPCs reliably relieve breathlessness and improve quality of life.¹⁴ In a prospective study, about 85% of patients reported symptom relief after IPC placement.¹⁵

An interesting bonus of IPCs is that about a quarter to a third of patients develop spontaneous pleurodesis over time, meaning the pleural space seals itself from the ongoing drainage and the catheter can eventually be removed.¹⁶ In one prospective study, pleurodesis occurred in about 28% of malignant effusion cases.¹⁵ Complications include catheter blockage (around 16% of patients), chest pain (13%), loculation of fluid (9%), and pleural infection (9%).

IPC Versus Talc Pleurodesis

Head-to-head trials have found that both approaches relieve breathlessness equally well. The TIME2 trial found no significant difference in dyspnea over the first 42 days, and at six months the IPC group actually reported better breathlessness scores.¹⁷ IPC patients had a dramatically shorter initial hospital stay (median zero days versus four days for talc) and needed fewer additional pleural procedures. However, they experienced more adverse events overall. A Dutch trial echoed these findings: IPC patients spent fewer days in the hospital and needed fewer re-interventions, though patients receiving talc pleurodesis reported less breathlessness at rest at six weeks.¹⁸

A meta-analysis of the randomized data summarized the trade-off: talc pleurodesis achieved higher pleurodesis rates, less total drainage volume, and fewer minor complications like catheter blockage and skin infection, but required more procedures and longer hospitalization. Neither approach showed an advantage in survival or quality of life.¹⁹ In practice, the choice often comes down to patient preference and life expectancy: those who want minimal hospital time and can manage drainage at home tend to favor IPCs, while those who want a one-time procedure and are fit enough for hospitalization may prefer talc.

The Problem of Trapped Lung

One complication that changes the treatment calculus is trapped lung, where malignant tissue or adhesions prevent the lung from expanding fully after fluid is drained. When the lung cannot re-expand to contact the chest wall, pleurodesis will not work because the two pleural surfaces never come together. This condition, sometimes called “oncothorax” when it results from extensive malignant encasement, is notoriously difficult to treat.²⁰

IPCs are generally the default management for trapped lung, as they allow ongoing intermittent drainage without requiring the lung to fully expand. A five-year study using tunneled catheters in this population found they provided effective palliation while keeping patients out of the hospital, an important consideration for people with limited life expectancy.²¹ More aggressive options like surgical decortication or pleurectomy exist but are reserved for patients with reasonable performance status and limited metastatic disease elsewhere.

Systemic Therapy and the Role of Immunotherapy

Because pleural metastasis signals advanced cancer, systemic treatment, meaning chemotherapy, targeted therapy, or immunotherapy, is the backbone of disease control. In recent years, researchers have been asking how well immune checkpoint inhibitors (ICIs) work specifically in patients whose cancer has spread to the pleura.

The picture is mixed. A large French cohort study found that the presence of pleural or peritoneal metastasis was independently associated with worse outcomes on checkpoint inhibitor therapy in non-small cell lung cancer. Patients with these metastases and reduced performance status had less than a 10% chance of benefiting from treatment.²² That does not mean immunotherapy is futile for these patients, but it suggests the pleural microenvironment may be immunosuppressive, blunting the effectiveness of drugs designed to unleash the immune system.

Combining checkpoint inhibitors with chemotherapy appears to help. A multicenter retrospective study in non-small cell lung cancer patients with MPE found that adding immunotherapy to chemotherapy as first-line treatment extended the time before cancer progressed (median roughly 7.4 months versus 5.7 months for chemotherapy alone).²³ Overall survival was numerically better but did not reach statistical significance in this study, leaving the question of a long-term survival benefit still open.

Hyperthermic Intrapleural Chemotherapy

A more aggressive local approach involves pumping heated chemotherapy solution directly through the pleural space during surgery, a technique called intrapleural hyperthermic chemotherapy (or IPHC/HIPEC adapted for the chest). The heat, typically maintained around 43°C at the pleural surface, is thought to enhance the killing power of the drugs while directly targeting tumor deposits on the pleura.

A meta-analysis comparing heated intrapleural chemotherapy to room-temperature intrapleural chemotherapy found that the heated approach produced significantly better objective response rates and quality-of-life improvement, with similar rates of side effects like fatigue and low blood counts.²⁴ One study using this technique under video-assisted thoracoscopy in lung cancer patients reported that effusion was controlled in all treated patients and the median survival reached about 22 months.²⁵ Another study found median survival of nearly 16 months in the hyperthermic group, compared with six months for talc pleurodesis and eight months for pleurectomy alone.²⁶

These results are encouraging, but the evidence comes from relatively small, often non-randomized studies. The procedure requires general anesthesia and surgical expertise, limiting it to patients who are fit enough and to centers with the necessary infrastructure. It remains an option discussed on a case-by-case basis rather than a standard-of-care approach.

Predicting Survival

Not all patients with pleural metastasis have the same prognosis, and predicting how long someone might live matters practically. It influences whether aggressive interventions are appropriate, whether hospitalization for pleurodesis makes sense, or whether an IPC and home-based care is the wiser path.

The most widely studied prognostic tool is the LENT score, which combines four factors: pleural fluid characteristics, how far the cancer has spread, a blood marker of inflammation, and the patient’s functional status. A validation study of 120 patients found that LENT effectively stratified patients into low, moderate, and high risk groups, with an overall median survival of about two months from first drainage. The score predicted mortality at one, three, and six months with acceptable discrimination.²⁷ An external validation study confirmed that both LENT and a newer tool, the PROMISE score, showed reasonable predictive ability for survival at three, six, and twelve months.²⁸

A more recently proposed model called the GASENT score has shown slightly better accuracy than LENT in a head-to-head comparison, outperforming it at the one, three, and six-month time points.²⁹ Prognostic scores are far from perfect on an individual level, but they help clinicians and patients have more informed conversations about treatment goals.

Quality of Life After Treatment

For a condition where cure is rarely the goal, quality of life is arguably the most important outcome measure. The evidence here is reassuring: effective drainage, whether through pleurodesis or an IPC, meaningfully improves how patients feel. A study of patients receiving tunneled catheters found significant improvements in breathlessness at two weeks that were maintained out to 14 weeks in those who survived, along with gains in overall health status, fatigue, and cough.³⁰ Among lung cancer patients specifically, another prospective study showed significant improvement in breathlessness-related quality-of-life measures after catheter placement.³¹

Cost also matters, especially when treatment is palliative. A cost-effectiveness analysis found that talc pleurodesis was less costly than an IPC under typical assumptions, but that IPCs became the more cost-effective option when life expectancy dropped below about six weeks.³² This makes sense: a patient who is unlikely to survive long enough to benefit from a pleurodesis hospital stay gets more value from going home the same day with a catheter.

Liquid Biopsy From Pleural Fluid

An emerging area of research treats the effusion fluid itself as a rich diagnostic resource beyond simple cytology. Pleural fluid contains circulating tumor DNA, microRNAs, and circulating tumor cells in higher concentrations than blood plasma, making it a potentially powerful “liquid biopsy.”³³ This matters because identifying specific genetic mutations in the tumor, like EGFR mutations or ALK rearrangements in lung cancer, can determine whether a patient is eligible for targeted therapies that dramatically outperform standard chemotherapy.

When tissue biopsy is difficult or risky, analyzing the fluid already being drained for symptoms could serve a dual purpose: symptom relief and molecular profiling in one procedure. This approach is still being refined, and standardized protocols for extracting and analyzing tumor-derived material from pleural fluid are not yet universal. But for patients who need answers quickly and cannot easily undergo a tissue biopsy, it represents a practical and minimally invasive option that is gradually entering clinical use.

1
PubMed Central. Pleural involvement in lung cancer
2
European Respiratory Review. Malignant pleural effusion: from bench to bedside
3
PubMed. Malignancy metastatic to the pleura
4
PubMed. Indeterminate pleural metastasis on contrast-enhanced chest CT in non-small cell lung cancer: improved differential diagnosis with (18)F-FDG PET/CT
5
PubMed Central. 18 F-FDG PET/CT Detection of Extensive Pleural Metastasis in Rare Malignancy Thymoma
6
PubMed Central. Differentiating malignant pleural mesothelioma and metastatic pleural disease based on a machine learning model with primary CT signs: A multicentre study
7
Thorax. Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: systematic review and meta-analysis
8
PubMed Central. Evaluation of pleural fluid cytology for the diagnosis of malignant pleural effusion: a retrospective cohort study
9
PubMed Central. Pleural controversies: image guided biopsy vs. thoracoscopy for undiagnosed pleural effusions?
10
European Respiratory Review. Diagnostic performance and safety of image-guided pleural biopsy and medical thoracoscopy for undiagnosed exudative pleural effusion: a systematic review and network meta-analysis
11
PubMed. Talc pleurodesis in malignant pleural effusion: a systematic review and meta-analysis
12
Cochrane Database of Systematic Reviews. Medical thoracoscopy, thoracoscopy and chemical pleurodesis in malignant pleural effusion
13
American Journal of Respiratory and Critical Care Medicine. Prospective Randomized Comparison of Thoracoscopic Talc Poudrage under Local Anesthesia versus Bleomycin Instillation for Pleurodesis in Malignant Pleural Effusions
14
PubMed Central. Indwelling pleural catheters: complications and management strategies
15
PubMed Central. Indwelling pleural catheter efficacy and safety in malignant vs. non-malignant pleural effusions: a prospective study
16
PubMed. Managing malignant pleural effusion with an indwelling pleural catheter: factors associated with spontaneous pleurodesis
17
JAMA. Effect of an Indwelling Pleural Catheter vs Chest Tube and Talc Pleurodesis for Relieving Dyspnea in Patients With Malignant Pleural Effusion: The TIME2 Randomized Controlled Trial
18
PubMed. A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14)
19
PubMed Central. Talc pleurodesis versus indwelling pleural catheter among patients with malignant pleural effusion: a meta-analysis of randomized controlled trials
20
PubMed Central. Management of Malignant Lung Entrapment, the Oncothorax
21
PubMed. Malignant pleural effusion in the presence of trapped lung. Five-year experience of PleurX tunnelled catheters
22
PubMed Central. Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France
23
PubMed Central. Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study
24
PubMed Central. Efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy for malignant pleural effusion: a meta-analysis
25
PubMed Central. Intrapleural perfusion thermo-chemotherapy for pleural effusion caused by lung carcinoma under VATS
26
Respiratory Medicine. Intrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies
27
PubMed Central. Validating LENT score in malignant pleural effusion
28
ERJ Open Research. External validation of the LENT and PROMISE prognostic scores for malignant pleural effusion
29
Archivos de Bronconeumología. Predictors of Survival in Metastatic Malignant Pleural Effusions: The GASENT Score
30
Respiration. The Impact of Tunneled Pleural Catheters on the Quality of Life of Patients with Malignant Pleural Effusions
31
PubMed. Quality-of-Life assessment in malignant pleural effusion treated with indwelling pleural catheter: a prospective study
32
PubMed Central. Treatment of Malignant Pleural Effusion: PleuRx Catheter or Talc Pleurodesis? A Cost-Effectiveness Analysis
33
PubMed Central. Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions